CereScape Pty Ltd
This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).
仅展示当前所选商店地区的已观测下载价格。点击区域比价可查看各国家和地区的换算价格。
当前在 Apple 公共 App Store 页面可见的项目,可能不等同于 App Store Connect 中的完整目录。
This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).
It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban.
Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information.
Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.
根据最新观测到的 App Store 数据快速解答。
最新观测到的下载价格为 59.000đ。请打开 App Store 官方链接确认当前结算价格。
Apple 公开页面目前在该商店显示 0 个购买项目,公开列表可能不完整。
会。App Store 价格可能因商店、币种、税费和开发者定价而不同,目前已收集 1 个地区观测。